Category: Press Releases

Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer

AUSTIN, TX, April 2, 2017 – Genprex, Inc. announced new pre-clinical data which reveal that TUSC2 (formerly known as FUS1, the active anti-cancer agent in OncoprexTM) in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlated with prolonged survival in mice….

Read More

Genprex to Present at Two Upcoming Conferences

AUSTIN, Texas, March 27, 2017 — Genprex, Inc., a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, today announced that Julien Pham, MD, the Company’s Chief Operating Officer, is scheduled to present a corporate overview at two upcoming healthcare investor conferences.

Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, March 28, 2017 at 3:00 PM EDT in New York, NY

BioCentury 24th Annual Future Leaders in Biotech Industry – Friday, April 7, 2017 at 11:20 AM EDT in New York, NY

About Genprex

Genprex is a privately held, clinical-stage biopharmaceutical company developing immunogene therapy treatments to increase the treatment options for various cancers….

Read More

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer

AUSTIN, TX, January 6, 2017 – Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®) for the treatment of late stage non-small cell lung cancer (NSCLC) patients.

The clinical trial, which is ongoing at The University of Texas MD Anderson Cancer Center, is designed to evaluate the Oncoprex/erlotinib treatment combination in up to 57 patients with late stage NSCLC, with and without EGFR mutations, who have failed at least two drug regimens….

Read More

Genprex To Present at Biotech Showcase 2017

AUSTIN, TX, December 19, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference, one of largest healthcare focused investor conferences in the U.S….

Read More

Genprex Retains ICR Healthcare as Integrated Strategic Communications Counsel

AUSTIN, TX, December 7, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, today announced that it has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program. The program will combine investor relations, public relations and digital communications to advance the objective of raising the profile of Genprex and its lead candidate Oncoprex, which is currently in a Phase II trial for the treatment of non-small cell lung cancer (NSCLC)….

Read More

Genprex Expands Executive Management Team and Completes Funding

AUSTIN, TX, November 4, 2016 – Genprex, Inc. a biopharmaceutical company focused on the development of revolutionary immunogene therapy treatments, announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer. Dr. Pham joins Genprex after previously serving as Founder and Chief Medical Officer at RubiconMD and as a clinical faculty member at Harvard Medical School….

Read More

Genprex Signs Capital Markets Advisory Agreement with Network 1 Financial as Part of an Overall Financing Plan

AUSTIN, TX, August 24, 2016 – Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate. Upon completion of the initial phase of this agreement, which is expected to occur well before the end of this year, the Company intends to put in place an overall plan with Network 1 Financial to provide for its immediate and long term capital needs and for the ultimate goal of being a public company….

Read More

Genprex Begins Phase II Clinical Trial for Lung Cancer

AUSTIN, TX, May 20, 2014 – Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways.

Read More

Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients

AUSTIN, TX, April 26, 2012

A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients. The clinical trial results were published April 26, 2012 in a paper entitled, “Phase I Clinical Trial of Systemically Administered …

Read More

Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206

CHICAGO, IL and AUSTIN, TX, April 2, 2012 – Genprex, Inc.

New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL.  The study, “Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC” (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center. …

Read More